Company Profile

Attometrics LLC
Profile last edited on: 7/27/2017      CAGE: 6YAB4      UEI: EKGEQNEJNUH4

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

15013 South 24th Way
Phoenix, AZ 85048
   (480) 759-7001
Location: Single
Congr. District: 09
County: Maricopa

Public Profile

Attometrics, Inc. develops and commercializes technology for detecting biomarkers to identify potential cancers and infectious diseases. The company sells an automated, multiplexed detection system that can handle high sample throughput to detect and identify groups of biomarkers for cancer and infectious diseases. The firm's patented technology quickly detects proteins, DNA and metabolites of interest in smaller amounts than is possible with current methods. The time-to-results is as little as 30 minutes as compared to one to six days for standard analyses. The companyÂ’s new STEC-DX (Shiga toxin-producing E. coli diagnostics) provides rapid screening for infection by E. coli O157:H7 and other bacterial strains that produce deadly Shiga toxin proteins. Infection by as few as 10 cells of STEC can be fatal due to the effects of the Stx1 and Stx2 toxins, which are not always produced by the bacteria. The worst effects of the toxin can be avoided if treated within 24 hours of infection. AttometricsÂ’ STEC-DX is the only method capable of directly detecting the presence of such small amounts of toxin within that timeframe.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2016 1 NIH $149,265
Project Title: Single-Molecule Analyte Detection by Molecular Motor-driven Nanodevices

Key People / Management

  Wayne D Frasch -- Founder and Chief Executive Officer

Company News

There are no news available.